Aren O, Samtani S, Frelinghuysen M, et al. - In South American patients suffering from non-small cell lung cancer (NSCLC), researchers conducted this retrospective review to assess the response rates as well as toxicity with 75 mg/d dose of erlotinib (a reversible epidermal growth factor receptor [EGFR] inhibitor). They analyzed 18 cases of histologically confirmed EGFR mutation metastatic NSCLC (mNSCLC) managed with 75 mg/d erlotinib as the starting dose. The median progression-free survival and overall survival (OS) was reported to be 17 months and 23 months, respectively. The primary grade 1–2 toxicities included rash (44%) and diarrhea (22%). Grade 3–4 toxicity was not experienced and no cases of drug discontinuation were documented. Overall, findings demonstrated the good tolerability of a dose of 75 mg/d of erlotinib in the South American population with mutated mNSCLC. The observed benefits in progression-free survival and OS conferred by this dose were similar to those documented in the literature with the standard dose.